Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2017 | Next-generation BTK inhibitors and their value in CLL

Anthony Mato • 14 Aug 2017
iwCLL 2017
Chronic Lymphocytic Leukemia Acalabrutinib

Anthony Mato, MD, MSCE, from the Hospital of the University of Pennsylvania, Philadelphia, PA, talks to us about next-generation BTK inhibitors such as acalabrutinib and their results in clinical trials, but notes that long-term follow-up is still required to assess their effectiveness. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

More from Anthony Mato

1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals